AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
February 23 2023 - 4:15PM
Business Wire
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T cell
immunotherapy company, today announced the appointment of Derek
Adams, Ph.D., to its Board of Directors, effective March 1, 2023.
Dr. Adams brings more than two decades of experience leading the
manufacturing of biologic and gene therapies at all stages of
development.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230223005810/en/
Derek Adams, Ph.D. (Photo: Business
Wire)
“I am thrilled that Derek is joining AlloVir’s Board of
Directors at this important time as the Company looks toward the
completion of our posoleucel Phase 3 studies, and potential
regulatory submissions and commercial launches. His experience
successfully advancing the manufacturing of complex biologic and
gene therapies from clinical development to commercialization will
be a tremendous asset as we drive posoleucel through Phase 3 and
beyond,” said Diana Brainard, M.D., Chief Executive Officer,
AlloVir.
As Dr. Adams joins, AlloVir Board member Ansbert Gadicke, M.D.,
has advised the Company that he will step down at the end of this
month. Dr. Gadicke joined the Board in September 2018 and has
helped to guide AlloVir’s growth from an early clinical stage
company at the time of its initial public offering in July 2020 to
its current state as a late-clinical stage company with three
ongoing Phase 3 registrational studies.
“I would like to thank Ansbert for his significant contributions
to AlloVir. His experience building leading biopharmaceutical
companies has helped shape AlloVir’s strategy and position the
company for continued success as we plan for the next phase of our
growth,” said Dr. Brainard.
Dr. Adams has extensive experience in building manufacturing
capabilities and navigating the regulatory Chemistry, Manufacturing
and Controls (CMC) landscape from development through
commercialization for advanced medicinal products including cell
therapies. He currently serves as Chief Executive Officer of
Stellular Bio, a private biotechnology company pioneering a
platelet-inspired cell therapy platform for regenerative medicine,
and previously served as President and Chief Executive Officer of
PlateletBio. Prior to these roles, Dr. Adams spent more than two
decades leading CMC for clinical- and commercial-stage biologics
and gene therapy companies. He served as Chief Technology and
Manufacturing Officer at bluebird bio, Senior Vice President of CMC
at Evelo Biosciences, and Vice President of Technical and Strategic
Product Development at Alexion Pharmaceuticals. Dr. Adams received
his Ph.D. in Chemical Engineering from the University of Minnesota
and a B.S. in Chemical Engineering with High Distinction from
Worcester Polytechnic Institute.
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company
with a focus on restoring natural immunity against life-threatening
viral diseases in pediatric and adult patients with weakened immune
systems. The company’s innovative and proprietary technology
platforms leverage off-the-shelf, allogeneic, single- and
multi-virus-specific T cells for patients with T cell deficiencies
who are at risk from the life-threatening consequences of viral
diseases. AlloVir’s technology and manufacturing process enable the
potential for the treatment and prevention of a spectrum of
devastating viruses with each single allogeneic cell therapy. The
company is advancing multiple mid- and late-stage clinical trials
across its product portfolio. For more information, visit
www.allovir.com or follow us on Twitter or LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding AlloVir’s development and regulatory status of our
product candidates, the planned conduct of its preclinical studies,
and clinical trials and its prospects for success in those studies
and trials, and its strategy, business plans and focus. The words
“may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties, and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those related to AlloVir’s financial results, the
timing for the initiation and successful completion of AlloVir’s
clinical trials of its product candidates, whether and when, if at
all, AlloVir’s product candidates will receive approval from the
U.S. Food and Drug Administration, or FDA, or other foreign
regulatory authorities, competition from other biopharmaceutical
companies, the impact of the COVID-19 pandemic on AlloVir’s product
development plans, supply chain, and business operations and other
risks identified in AlloVir’s SEC filings. AlloVir cautions you not
to place undue reliance on any forward-looking statements, which
speak only as of the date they are made. AlloVir disclaims any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions, or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent AlloVir’s views only as of the date hereof and should not
be relied upon as representing its views as of any subsequent
date.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230223005810/en/
Media and Investor: Sonia Choi AlloVir
schoi@allovir.com
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Jun 2024 to Jul 2024
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Jul 2023 to Jul 2024